Marcus Has Been Sober Eight Months. Nothing Feels Good Yet. His Brain Is Doing Exactly What It Should.

Marcus is 34, lives in Phoenix, and has been off methamphetamine for eight months. He goes to meetings. He’s working with a counselor through a county-funded program. He’s got a stable place to sleep for the first time in three years. By every external measure — the ones he was told to measure by — he’s doing it right.

And yet.

“Everything tastes like water,” he told his counselor in a session last April. He meant it literally and not. The coffee he used to love, the music he used to play on guitar, his daughter’s laugh when she comes to visit on Sundays — it’s there, he knows it’s there, but it’s coming from behind glass. He watches himself respond to things. He doesn’t feel them responding.

His counselor ordered a depression screen. The PHQ-9 came back at seven — below the clinical threshold for major depressive disorder. She referred him to a psychiatrist anyway, who considered prescribing an antidepressant. Marcus told him it wasn’t depression, exactly, it was something else. He didn’t have a word for it. Nobody had given him one.

Methamphetamine recovery isn’t just hard because sobriety is hard — it’s hard because meth chemically disables the part of your brain that makes anything feel worthwhile, and the field has known this for more than twenty years without making sure people leaving detox know it too.

The word Marcus needed is anhedonia — and before I explain what it means clinically, let me say it plainly first: the inability to feel pleasure. Not sadness. Not hopelessness. The specific absence of the thing that makes ordinary moments feel like they matter. Meth specifically, more than almost any other drug, produces this, and it lasts long enough to end recoveries that would otherwise hold.

What Meth Does to the Engine of Wanting

The part of your brain that generates “wanting” — not just wanting drugs, but wanting to eat, to connect, to try, to feel the small satisfaction of finishing something — is a circuit that runs primarily on dopamine. Dopamine isn’t pleasure exactly; it’s closer to the signal that tells your brain this is worth pursuing. It motivates. It directs attention. It is, in some sense, the neurochemical engine of caring about things.

Methamphetamine floods this system. A single dose releases somewhere between five and ten times the dopamine that a natural reward like food or sex does — a tidal wave where nature intended a wave. The brain responds the way any overwhelmed system does: it adapts. To prevent the signal from becoming meaninglessly loud, it downregulates. It reduces the number of receptors listening. It turns down the volume on its own machinery.

This adaptation is efficient and devastating. It is efficient because it prevents the dopamine system from being permanently fried by the flood. It is devastating because when the flood stops — when you stop using meth — the volume stays turned down.

Not for a few days. Not for a few weeks.

Research by Nora Volkow and colleagues published in the Journal of Neuroscience in 2001 imaged the brains of methamphetamine users at three points in time: during active use, after one month of abstinence, and after 12 to 24 months of abstinence. The finding was stark: the density of dopamine transporters — the proteins that help the brain recycle and regulate dopamine — was reduced by 15 to 24 percent in meth users compared to people who had never used. At one month out, the gap was still nearly as wide. At 12 months, it had narrowed significantly. At 24 months, most subjects were approaching normal levels.

Twelve to twenty-four months.

That is the timeline Marcus is living inside. His brain is doing exactly what neuroscience predicts it would do eight months out from heavy methamphetamine use: trying to rebuild the machinery that meth dismantled.

The Name Nobody Gives You at Discharge

What Marcus is experiencing has a clinical name that most discharge planning documents don’t include: Post-Acute Withdrawal Syndrome, or PAWS. The acute phase of meth withdrawal — the crash, the exhaustion, the acute cravings, the agitation — typically resolves in one to two weeks. PAWS is what comes after: a protracted period, lasting six to eighteen months, of symptoms that include anhedonia, cognitive fog (difficulty concentrating, slower processing), disturbed sleep, and intermittent cravings that arrive without obvious triggers.

The acute phase of meth withdrawal — the crash, the exhaustion, the acute cravings, the agitation — typically resolves in one to two weeks.

PAWS is not a formal DSM-5 diagnosis, which is part of why Marcus’s psychiatrist reached for a depression screen rather than a PAWS framework. The symptom overlap is real and important to distinguish: major depressive disorder and PAWS both produce anhedonia, fatigue, and sleep disturbance. The distinction matters for treatment. Standard SSRIs and SNRIs — the medications first-line for depression — act primarily on serotonin pathways, not dopamine. For anhedonia rooted in dopamine system disruption from meth use, the evidence base for SSRIs is, in the measured language of addiction medicine reviews, thin.

This is not a small error. It means people in early meth recovery are frequently started on medications that address the wrong neurotransmitter system, don’t notice much improvement, and conclude either that medication doesn’t help them or that something is more fundamentally wrong. Some of those people relapse. Some of them were measuring their recovery against a baseline that won’t be available to them for another twelve months.

If you are reading this in month six or eight of recovery from meth, and everything still feels flat: you are not failing. You are in the middle of the most biologically demanding part of the process. The machinery is coming back online. The timeline is long and it is real.

The History That Made This a Policy Failure

In the early 1990s, American emergency rooms, criminal courts, and addiction treatment centers were absorbing the first major waves of the crack cocaine epidemic. Crack — smoked freebase cocaine — acted on the dopamine system differently than injected cocaine and triggered a pattern of rapid escalation and intensive use that counselors and doctors in the field had not seen before.

NIDA researchers began asking what they thought was a straightforward question: why were stimulant patients so much harder to treat than alcohol or opioid patients? Alcohol withdrawal, addressed with benzodiazepines and medical monitoring, resolved over days to weeks. Heroin users treated with methadone or naltrexone had measurable outcomes that improved over months. Stimulant patients — crack, then powder cocaine, then methamphetamine — seemed to cycle through treatment programs and back to use at rates that defied the interventions available.

The imaging studies that followed — Volkow’s work among the most significant — gave the field an answer it didn’t fully act on: the stimulant recovery process operates on a different timescale because the neurological damage operates on a different timescale. The field knew this by the early 2000s. What it did not do was build it into the standard of care. Discharge planning for meth treatment, in most programs today, does not include a conversation about the 12 to 24-month dopamine recovery timeline, what anhedonia is and why to expect it, or how to distinguish PAWS from clinical depression. The knowledge that would have helped Marcus know what he was experiencing was not missing from addiction science. It was missing from his discharge paperwork.

Why Contingency Management Works When Nothing Feels Good

Here is where the science gets genuinely useful, and where the policy moment matters:

Contingency management — providing small, tangible rewards for drug-negative urine screens — has more than 200 randomized controlled trials behind it. It is, in the consensus of addiction science, the most evidence-based behavioral treatment available for stimulant use disorder. And part of why it works is directly related to the neurobiology above.

When the internal dopamine signal is turned down — when meth recovery has left the reward system running at diminished capacity — a reliable, immediate, external reward provides something the recovering brain cannot reliably generate on its own. The $10 gift card doesn’t bribe someone into sobriety. It provides a dopamine signal during the period when the brain’s ability to generate its own is compromised. It is, in this sense, not a behavioral manipulation but a neurological support.

It is, in this sense, not a behavioral manipulation but a neurological support.

The evidence bears this out at scale. California’s Recovery Incentives Program, now available through CalAIM, had enrolled nearly 3,400 people as of early 2025. Approximately 75 percent of submitted urine samples tested negative for stimulants — a figure that would be remarkable for any treatment modality. The program is expanding to more counties. Five states — California, Delaware, Hawaii, Montana, and Washington — now have CMS approval to cover contingency management as a Medicaid benefit.

A 2021 trial published in the New England Journal of Medicine (the ADAPT-2 study) found that the combination of extended-release naltrexone and bupropion — medications already approved for other conditions — produced a meaningful reduction in meth use compared to placebo. The effect was modest: 13.6 percent of urine samples negative in the active group versus 2.5 percent for placebo. But it was the first positive Phase 3 trial for any medication in methamphetamine use disorder. It showed that the pharmacological door, long closed, was not permanently locked.

For providers: if you are seeing patients in meth recovery between months three and eighteen, please screen explicitly for PAWS using the established PAWS symptom checklist (cognitive fog, anhedonia, sleep disruption, episodic cravings without trigger). The symptoms overlap with depression, and the treatment is not the same. HHS/ASPE’s 2023 guidance on contingency management includes implementation frameworks that primary care clinicians can adapt. Referring patients to CM programs during PAWS — when external motivation is most valuable — is not just best practice. It is the treatment most aligned with what is actually happening in the brain.

What the Grey Looks Like From Inside It

If you have eight months from meth and you feel like you are going through the motions of a life you cannot feel, this is what I want you to know, not as a clinician explaining a condition but as something the evidence says plainly:

You are not broken. You are not in denial. You are not secretly still using. You are not as far from recovery as the grey feels. The part of your brain that generates “this matters” is coming back. It runs on dopamine. Meth turned it down. It takes twelve to twenty-four months to turn back up. You are somewhere in the middle of that.

The grey has a timeline. The timeline is real. You are moving through it.

Find a program that offers contingency management if you can — your state’s Medicaid program may now cover it, depending on where you are. Tell your treatment provider what anhedonia is and ask if that’s what you’re experiencing. If they don’t know the term, find the ASPE brief linked above and bring it with you. You deserve a clinician who can name what is happening in your brain.

---

Marcus picked up his guitar again in March, about ten months in. He told his counselor the first few times he played it still felt like going through the motions — muscle memory without meaning. He kept playing anyway. By April something had shifted, slightly. Not a revelation. Not a movie moment. Just the small signal he had been waiting for: this is worth doing. The machinery coming back online.

“It’s not like before,” he said. “But it’s there.”

That’s what twelve months out looks like for a lot of people in meth recovery. Not the life that meth promised and never delivered. Not the flatness of the middle months. Something more honest, and quieter, and real.

---

Resources: SAMHSA’s National Helpline 1-800-662-4357 (24/7, free, confidential). Find treatment programs that offer contingency management through Rize Recovery. For providers: the ASPE contingency management brief includes state implementation frameworks.